Differential expression of VEGF ligands and receptors in prostate cancer

Treatment selection in metastatic renal cell carcinoma: expert consensus

(2012) Bernard Escudier et al.   Nature Reviews Clinical Oncology

Vascular Endothelial Growth Factor Receptor-3 Directly Interacts with Phosphatidylinositol 3-Kinase to Regulate Lymphangiogenesis

(2012) Sanja Coso et al.   PLoS One

Vascular endothelial growth factor receptor-3 promotes breast cancer cell proliferation, motility and survival in vitro and tumor formation in vivo

(2011) Elena V. Kurenova et al.   CELL CYCLE

Phosphorylation of Akt and ERK1/2 Is Required for VEGF-A/VEGFR2-Induced Proliferation and Migration of Lymphatic Endothelium

(2011) Michael T. Dellinger et al.   PLoS One

Effects of VEGFR-3 phosphorylation inhibitor on lymph node metastasis in an orthotopic diffuse-type gastric carcinoma model

(2009) M Yashiro et al.   BRITISH JOURNAL OF CANCER

Targeting Angiogenesis Driven by Vascular Endothelial Growth Factors Using Antibody-Based Therapies

(2008) Axel Grothey et al.   CANCER JOURNAL

The Tyrosine Kinase Inhibitor Cediranib Blocks Ligand-Induced Vascular Endothelial Growth Factor Receptor-3 Activity and Lymphangiogenesis

(2008) C. A. Heckman et al.   CANCER RESEARCH

Differential response of primary tumor versus lymphatic metastasis to VEGFR-2 and VEGFR-3 kinase inhibitors cediranib and vandetanib

(2008) T. P. Padera et al.   MOLECULAR CANCER THERAPEUTICS

Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation

(2008) Tuomas Tammela et al.   NATURE

Prediction of lymphatic invasion by peritumoral lymphatic vessel density in prostate biopsy cores

(2008) Kenji Kuroda et al.   PROSTATE